Peptides

GHRP-6: Complete Guide to Dosing, Benefits, and Stacking

Medici

28 Apr 2026 — 6 min read

GHRP-6 (Growth Hormone Releasing Peptide-6) is one of the original synthetic growth hormone secretagogues — a hexapeptide studied in research contexts since the 1980s and still one of the most potent GH-stimulating compounds in the peptide toolkit. Unlike cleaner, more selective secretagogues that came after it, GHRP-6 delivers strong GH pulses, a pronounced appetite kick, and a basket of cytoprotective properties that have attracted researchers well beyond the bodybuilding world.

This guide covers everything researchers need to know about GHRP-6: how it works, what peer-reviewed studies show, practical dosing protocols, comparisons with GHRP-2 and Ipamorelin, and how to stack it effectively with GHRH analogs like CJC-1295.

What Is GHRP-6?

GHRP-6 is a synthetic hexapeptide analog of met-enkephalin with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. It belongs to the first generation of growth hormone secretagogues (GHSs) developed to stimulate endogenous GH release without administering exogenous human growth hormone directly.

GHRP-6 is classified as a research compound and is not approved by the FDA for any human therapeutic indication. All data referenced here comes from peer-reviewed research and established research-use dosing conventions.

Mechanism of Action: How GHRP-6 Works

GHRP-6 exerts its effects by binding to two distinct receptors:

GHS-R1a (Ghrelin receptor): The primary GH-releasing pathway. Binding here triggers a pulse release of endogenous growth hormone from the anterior pituitary gland, mimicking the natural ghrelin-mediated GH pulse that occurs in a fasted state.
CD36: A scavenger receptor involved in fatty acid uptake and cellular protection. CD36 activation turns on prosurvival pathways including PI-3K/AKT1 — responsible for GHRP-6's documented cytoprotective effects in cardiac, hepatic, neuronal, and gastrointestinal tissues.

This dual mechanism distinguishes GHRP-6 from newer, more selective secretagogues like Ipamorelin, which exclusively target GHS-R1a. The CD36 activity gives GHRP-6 tissue-protective capabilities entirely independent of GH release.

Because GHRP-6 acts on the ghrelin receptor — the same receptor governing hunger signaling — appetite stimulation is a pharmacological certainty. This makes pronounced hunger both a potential feature (caloric surplus goals, cachexia protocols) and a limitation (weight management contexts).

Research-Backed Benefits of GHRP-6

Growth Hormone Stimulation

GHRP-6 reliably produces significant GH pulses. Subcutaneous administration at standard doses produces a measurable serum GH spike within 15–30 minutes, peaking around 60 minutes and returning to baseline within 3–4 hours. Consistent use downstream elevates IGF-1 levels, driving the anabolic and lipolytic effects associated with GH axis optimization.

Muscle Growth and Body Composition

Elevated GH and IGF-1 from GHRP-6 support lean muscle hypertrophy, nitrogen retention, and improved protein synthesis. Research subjects combining GHRP-6 with a GHRH analog report notable improvements in body composition — particularly meaningful muscle gain and fat loss when paired with resistance training.

Connective Tissue Repair and Recovery

Growth hormone is a critical driver of collagen synthesis and connective tissue repair. GHRP-6's GH-pulsing activity has made it a widely-used research compound in joint recovery, tendon healing, and post-injury rehabilitation protocols — often combined with BPC-157 or TB-500 for synergistic tissue repair.

Sleep Quality Enhancement

GH is preferentially released during deep (slow-wave) sleep. Pre-bed GHRP-6 administration can amplify the natural nocturnal GH pulse, supporting improved sleep architecture and overnight recovery. Evening dosing is a staple of most GHRP-6 protocols.

Cytoprotective and Cardioprotective Effects

Among the most compelling research on GHRP-6 is its direct organ-protective activity. A 2024 study published in Frontiers in Pharmacology demonstrated that GHRP-6 prevents doxorubicin-induced myocardial and extra-myocardial damage by activating prosurvival mechanisms via CD36. A 2025 PMC study examined GHRP-6's role in improving post-infarct ventricular remodeling and systolic dysfunction in a permanent coronary ligation model. Earlier research documented cytoprotection across gastric mucosa, liver tissue, and neurons — indicating GHRP-6 has significant research value beyond GH release.

Anti-Inflammatory and Antioxidant Properties

GHRP-6 decreases reactive oxygen species (ROS) spillover, enhances endogenous antioxidant defenses, and reduces inflammatory signaling in preclinical models. These effects are largely CD36-mediated and independent of the GH axis, explaining why GHRP-6's cytoprotective benefits are observed even in non-GH contexts.

GHRP-6 Dosing Protocols

The following protocols reflect over two decades of research-use convention. They are not medical advice. GHRP-6 is for research purposes only.

Dose Range

100 mcg per injection: Starting dose — ideal for assessing appetite response and tolerability before increasing
200 mcg per injection: Most common research dose — optimal balance of GH output and side effect profile
300 mcg per injection: High-end dose used for maximum GH stimulation; increases cortisol and prolactin more significantly

Injection Frequency

GHRP-6 is typically administered 2–3 times daily:

2x/day: Morning (fasted) + pre-bed — practical for most research protocols
3x/day: Morning (fasted) + afternoon (fasted) + pre-bed — for maximum GH pulse frequency

Timing Is Critical

GHRP-6 must be administered in a fasted state. Elevated blood glucose and insulin blunt the GH response at the pituitary level. The protocol: wait at least 2 hours after the last meal, inject, then avoid carbohydrates and fats for 30–60 minutes post-injection to preserve the GH pulse. Water and black coffee are acceptable pre-injection.

Administration

Subcutaneous injection via insulin syringe (27–31 gauge) into the abdomen, thigh, or deltoid pinch. Reconstitute lyophilized GHRP-6 with bacteriostatic water; store reconstituted peptide refrigerated and use within 28–30 days.

Cycle Duration

Standard research cycles run 8–12 weeks. Extended continuous use risks GHS-R1a desensitization and diminishing GH responses. The recommended approach: 8 weeks on, 4 weeks off — or rotate between GHRP-6 and Ipamorelin to avoid receptor downregulation while maintaining coverage.

GHRP-6 vs GHRP-2 vs Ipamorelin

All three are ghrelin receptor agonists, but their selectivity profiles differ significantly — and the right choice depends on research goals:

GHRP-6

High GH potency with strong appetite stimulation and moderate cortisol/prolactin increase. The standout of the group for mass-building phases where caloric support is beneficial, and the only one with documented cytoprotective CD36 activity. Best for: mass gains, appetite support, recovery stacking, cardioprotective research.

GHRP-2

Highest GH potency of the three — maintains elevated GH levels over longer periods post-injection compared to GHRP-6. Moderate appetite stimulation but higher cortisol and ACTH elevations. Best for: maximum GH output when appetite stimulation must be moderated.

Ipamorelin

The most selective and well-tolerated GH secretagogue. Research published in European Journal of Endocrinology confirmed Ipamorelin does not raise ACTH or cortisol in levels significantly different from baseline GHRH stimulation, even at doses 200x the ED50 for GH release. No meaningful appetite stimulation. Best for: clean GH pulses, beginners, those sensitive to cortisol/prolactin fluctuations, and female research subjects.

Summary: Ipamorelin is the safest starting point. GHRP-2 is the step up for maximum GH output. GHRP-6 is the choice when appetite drive and cytoprotective properties are part of the research goal.

Stacking GHRP-6 with CJC-1295

The most researched GHRP-6 stack is co-administration with CJC-1295 No DAC (Mod GRF 1-29). The synergy is significant: GH pulses from the combination are typically 3–6x higher than GHRP-6 alone.

The mechanism: CJC-1295 No DAC primes the pituitary by occupying GHRH receptors, increasing the pool of releasable GH. GHRP-6 then triggers the pulse via GHS-R1a. Acting on different receptors, they produce multiplicative — not merely additive — GH release.

Standard protocol: 100–200 mcg GHRP-6 co-injected with 100 mcg CJC-1295 No DAC in the same syringe, 2–3x daily on an empty stomach. Both must be injected simultaneously to achieve the synergistic pulse.

CJC-1295 No DAC vs. With DAC: Always use the No DAC version for pulse-based stacking. CJC-1295 with DAC creates a sustained, blunted GHRH signal (half-life ~6–8 days) that prevents the sharp pituitary priming required for timed GHRP co-administration.

GHRP-6 + BPC-157 for Injury Recovery

For tissue repair and recovery protocols, GHRP-6 is frequently paired with BPC-157. The combination addresses tissue healing from complementary angles: GH-driven collagen synthesis and systemic anabolic signaling (GHRP-6) plus local growth factor upregulation and angiogenesis (BPC-157). They are injected separately and act on non-competing pathways.

Side Effects and Safety Profile

Expected Side Effects

Hunger surge: Intense appetite increase in the 30–60 minutes post-injection — the most consistently reported and predictable effect. Plan meals or caloric intake around injection timing.
Water retention: Mild fluid retention, particularly in the first few weeks, driven by GH and downstream IGF-1.
Cortisol and prolactin elevation: Modest increases at standard doses (200 mcg); generally subclinical. Higher doses or long cycles may produce fatigue, mood fluctuations, or mild gynecomastia in sensitive individuals.
Injection site reactions: Transient redness, minor swelling, or itching — standard with all subcutaneous peptide injections.
Tingling/numbness: Occasionally reported at higher doses.

Hormonal Effects at Different Doses

Research pharmacology data shows: at ~1 mcg/kg IV (diagnostic dose), cortisol increases 10–25% from baseline and ACTH 15–30% — generally clinically insignificant. At 2 mcg/kg+ IV, cortisol increases 30–50% and ACTH 40–60%. Subcutaneous dosing at 100–300 mcg produces lower systemic peaks than IV administration.

Receptor Desensitization

Continuous use leads to GHS-R1a downregulation and progressively blunted GH responses. Management: cycle 8 weeks on/4 off, or alternate GHRP-6 with Ipamorelin every 8 weeks.

Long-Term Safety Considerations

Formal long-term controlled human studies are absent. Theoretical risks from any chronic GH/IGF-1 axis stimulation include insulin resistance, fluid retention, joint discomfort, and carpal tunnel syndrome. GHRP-6 is not FDA-approved for human use and remains classified as a research compound.

Conclusion

GHRP-6 occupies a unique space in the GH secretagogue landscape. Its dual receptor activity — potent GH pulsing via GHS-R1a and direct tissue protection via CD36 — gives it a profile that newer, more selective peptides like Ipamorelin cannot fully replicate. The pronounced appetite stimulation is its defining feature: a genuine advantage for mass-building and recovery contexts, and a consideration to manage in fat-loss protocols.

At standard research doses (100–200 mcg subcutaneous, 2–3x daily, fasted), GHRP-6 is backed by decades of peer-reviewed research spanning GH optimization, connective tissue repair, and organ protection. Stack it with CJC-1295 No DAC for maximum GH output. Pair it with BPC-157 for injury recovery. Cycle appropriately to preserve receptor sensitivity and monitor hormonal markers on extended protocols.

Disclaimer: GHRP-6 is a research compound not approved for human use by the FDA. This article is for educational and informational purposes only and does not constitute medical advice.